Presorted First Class Mail US Postage PAID Permit # 906 Bellmawr NJ Professor and Associate Chair of Medicine Director, Clinical Research Service Center Wayne State University School of Medicine Detroit, MI Vice Chief of Medicine Baylor University Medical Center Dallas, TX W. Frank Peacock, MD, F, FACC Professor, Medicine Associate Chair and Research Director Baylor College of Medicine/Ben Taub General Hospital Houston, TX Register Online! South Convention Center VindicoMedEd.com/Xxxxxx Level 2 Director of Research, Denver Nephrology Research Colorado Kidney Care Denver, CO VINDICO medical education 6900 Grove Road Building 100 Updates on the Current Management of a Complex Condition /-certified Activity /-certified Activity Peter A. McCullough, MD, MPH W. Frank Peacock, MD This continuing medical education activity is provided by This activity is supported by an educational grant from ZS Pharma, Inc. This symposium is not part of the official 16 conference educational program as planned by s Educational Meetings Committee.
Overview is an electrolyte abnormality marked by elevated serum potassium levels that can induce adverse electrophysiologic changes, resulting in malignant arrhythmias and death. A major risk factor for the development of hyperkalemia is chronic kidney disease (CKD), but medications prescribed for other conditions that are freuently comorbid with CKD, including cardiovascular disease and diabetes mellitus, can also cause hyperkalemia. In the emergency department, initial intervention for acute hyperkalemia may include sodium polystyrene sulfonate (given orally and/or via retention enema), intravenous diuretics, insulin glucose administration, intravenous saline, and, to a lesser extent, intravenous bicarbonate or calcium, with treatments that target intracellular potassium shifts or enhance renal and gastrointestinal elimination. In addition, sodium zirconium cyclosilicate is in late-stage clinical trials for the treatment of both acute and chronic hyperkalemia, providing another therapeutic option future. This activity will focus on the pathophysiology and underlying issues that induce hyperkalemia, as well as the management of hyperkalemia by the emergency medicine physician or other health care professionals involved treatment of these patients. Learning Objectives Agenda Introduction and Pretest 6:40 pm 6:50 pm Recognizing 6:50 pm 7:05 pm 7:05 pm 7:10 pm 7:10 pm 7:25 pm 7:25 pm 7:35 pm 7:35 pm 7:50 pm Outline the pathophysiology of hyperkalemia and potential electrocardiographic changes it may cause. Evaluate the efficacy and safety data of new and emerging treatments for hyperkalemia. Differentiate among the new and emerging agents for hyperkalemia for improved treatment selection. Customized learning at your fingertips you choose the case! 6:30 pm 6:40 pm Upon successful completion of this educational activity, participants should be better able to: Describe the signs and symptoms of hyperkalemia. 7:50 pm 8:00 pm Recognizing and Understanding W. Frank Peacock, MD, F Management of New and Emerging Potassium Binders for Posttest / Question and Answer Register Online Today! Vindico.com/101516 /-certified Activity Contact Information: E-mail: COMPLIMENTARY REGISTRATION Seating is Limited MeetingRegistration@Vindico.com Toll-free: 877-307-5225, ext. 219 or 476 Current Management of Case Wrap-up Audience-driven Case-based Learning Phone: 856-994-9400, ext. 219 or 476 Fax: 856-251-0278 Mail: Registration 6900 Grove Road First Name M.I. Last Name Preferred Mailing Address (Home/Business) City State Zip Code Country Daytime Phone Evening Phone Fax E-mail Date of Birth (for tracking credits ONLY) National Provider Identifier (NPI) Medical License Number Medical License State Target Audience The intended audience for this activity is emergency physicians and other health care professionals involved treatment of patients with hyperkalemia. Degree (please specify) Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation activity. Vindico will apply to the American College of Physicians for program approval. In accordance with the Accreditation Council for Continuing Medical Education s Standards for Commercial Support, all planners, teachers and authors involved development of content are reuired to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience., topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee. 2016 istockphoto.com/guvendemir/kotoffei MD/DO PhD MD, PhD PharmD/RPh PA RN/BSN/MSN NP Industry Other: How did you hear about this meeting? (multiple selections allowed) E-mail Advertisement Postcard Brochure Web site Word of mouth ADA compliance: In compliance with the Americans with Disabilities Act of 1990, we will make reasonable efforts to accommodate persons with disabilities. Please call with your reuests. Specialty (select one) Internal Medicine Cardiology Nephrology Medicine Other: Endocrinology Family Practice/General Practice Activity Reuest YES, I would like to receive information regarding future / activities related to this therapeutic area. Priority Code: 283-1 2 3
Overview is an electrolyte abnormality marked by elevated serum potassium levels that can induce adverse electrophysiologic changes, resulting in malignant arrhythmias and death. A major risk factor for the development of hyperkalemia is chronic kidney disease (CKD), but medications prescribed for other conditions that are freuently comorbid with CKD, including cardiovascular disease and diabetes mellitus, can also cause hyperkalemia. In the emergency department, initial intervention for acute hyperkalemia may include sodium polystyrene sulfonate (given orally and/or via retention enema), intravenous diuretics, insulin glucose administration, intravenous saline, and, to a lesser extent, intravenous bicarbonate or calcium, with treatments that target intracellular potassium shifts or enhance renal and gastrointestinal elimination. In addition, sodium zirconium cyclosilicate is in late-stage clinical trials for the treatment of both acute and chronic hyperkalemia, providing another therapeutic option future. This activity will focus on the pathophysiology and underlying issues that induce hyperkalemia, as well as the management of hyperkalemia by the emergency medicine physician or other health care professionals involved treatment of these patients. Learning Objectives Agenda Introduction and Pretest 6:40 pm 6:50 pm Recognizing 6:50 pm 7:05 pm 7:05 pm 7:10 pm 7:10 pm 7:25 pm 7:25 pm 7:35 pm 7:35 pm 7:50 pm Outline the pathophysiology of hyperkalemia and potential electrocardiographic changes it may cause. Evaluate the efficacy and safety data of new and emerging treatments for hyperkalemia. Differentiate among the new and emerging agents for hyperkalemia for improved treatment selection. Customized learning at your fingertips you choose the case! 6:30 pm 6:40 pm Upon successful completion of this educational activity, participants should be better able to: Describe the signs and symptoms of hyperkalemia. 7:50 pm 8:00 pm Recognizing and Understanding W. Frank Peacock, MD, F Management of New and Emerging Potassium Binders for Posttest / Question and Answer Register Online Today! Vindico.com/101516 /-certified Activity Contact Information: E-mail: COMPLIMENTARY REGISTRATION Seating is Limited MeetingRegistration@Vindico.com Toll-free: 877-307-5225, ext. 219 or 476 Current Management of Case Wrap-up Audience-driven Case-based Learning Phone: 856-994-9400, ext. 219 or 476 Fax: 856-251-0278 Mail: Registration 6900 Grove Road First Name M.I. Last Name Preferred Mailing Address (Home/Business) City State Zip Code Country Daytime Phone Evening Phone Fax E-mail Date of Birth (for tracking credits ONLY) National Provider Identifier (NPI) Medical License Number Medical License State Target Audience The intended audience for this activity is emergency physicians and other health care professionals involved treatment of patients with hyperkalemia. Degree (please specify) Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation activity. Vindico will apply to the American College of Physicians for program approval. In accordance with the Accreditation Council for Continuing Medical Education s Standards for Commercial Support, all planners, teachers and authors involved development of content are reuired to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience., topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee. 2016 istockphoto.com/guvendemir/kotoffei MD/DO PhD MD, PhD PharmD/RPh PA RN/BSN/MSN NP Industry Other: How did you hear about this meeting? (multiple selections allowed) E-mail Advertisement Postcard Brochure Web site Word of mouth ADA compliance: In compliance with the Americans with Disabilities Act of 1990, we will make reasonable efforts to accommodate persons with disabilities. Please call with your reuests. Specialty (select one) Internal Medicine Cardiology Nephrology Medicine Other: Endocrinology Family Practice/General Practice Activity Reuest YES, I would like to receive information regarding future / activities related to this therapeutic area. Priority Code: 283-1 2 3
Presorted First Class Mail US Postage PAID Permit # 906 Bellmawr NJ Professor and Associate Chair of Medicine Director, Clinical Research Service Center Wayne State University School of Medicine Detroit, MI Vice Chief of Medicine Baylor University Medical Center Dallas, TX W. Frank Peacock, MD, F, FACC Professor, Medicine Associate Chair and Research Director Baylor College of Medicine/Ben Taub General Hospital Houston, TX Register Online! South Convention Center VindicoMedEd.com/Xxxxxx Level 2 Director of Research, Denver Nephrology Research Colorado Kidney Care Denver, CO VINDICO medical education 6900 Grove Road Building 100 Updates on the Current Management of a Complex Condition /-certified Activity /-certified Activity Peter A. McCullough, MD, MPH W. Frank Peacock, MD This continuing medical education activity is provided by This activity is supported by an educational grant from ZS Pharma, Inc. This symposium is not part of the official 16 conference educational program as planned by s Educational Meetings Committee.
Overview is an electrolyte abnormality marked by elevated serum potassium levels that can induce adverse electrophysiologic changes, resulting in malignant arrhythmias and death. A major risk factor for the development of hyperkalemia is chronic kidney disease (CKD), but medications prescribed for other conditions that are freuently comorbid with CKD, including cardiovascular disease and diabetes mellitus, can also cause hyperkalemia. In the emergency department, initial intervention for acute hyperkalemia may include sodium polystyrene sulfonate (given orally and/or via retention enema), intravenous diuretics, insulin glucose administration, intravenous saline, and, to a lesser extent, intravenous bicarbonate or calcium, with treatments that target intracellular potassium shifts or enhance renal and gastrointestinal elimination. In addition, sodium zirconium cyclosilicate is in late-stage clinical trials for the treatment of both acute and chronic hyperkalemia, providing another therapeutic option future. This activity will focus on the pathophysiology and underlying issues that induce hyperkalemia, as well as the management of hyperkalemia by the emergency medicine physician or other health care professionals involved treatment of these patients. Learning Objectives Agenda Introduction and Pretest 6:40 pm 6:50 pm Recognizing 6:50 pm 7:05 pm 7:05 pm 7:10 pm 7:10 pm 7:25 pm 7:25 pm 7:35 pm 7:35 pm 7:50 pm Outline the pathophysiology of hyperkalemia and potential electrocardiographic changes it may cause. Evaluate the efficacy and safety data of new and emerging treatments for hyperkalemia. Differentiate among the new and emerging agents for hyperkalemia for improved treatment selection. Customized learning at your fingertips you choose the case! 6:30 pm 6:40 pm Upon successful completion of this educational activity, participants should be better able to: Describe the signs and symptoms of hyperkalemia. 7:50 pm 8:00 pm Recognizing and Understanding W. Frank Peacock, MD, F Management of New and Emerging Potassium Binders for Posttest / Question and Answer Register Online Today! Vindico.com/101516 /-certified Activity Contact Information: E-mail: COMPLIMENTARY REGISTRATION Seating is Limited MeetingRegistration@Vindico.com Toll-free: 877-307-5225, ext. 219 or 476 Current Management of Case Wrap-up Audience-driven Case-based Learning Phone: 856-994-9400, ext. 219 or 476 Fax: 856-251-0278 Mail: Registration 6900 Grove Road First Name M.I. Last Name Preferred Mailing Address (Home/Business) City State Zip Code Country Daytime Phone Evening Phone Fax E-mail Date of Birth (for tracking credits ONLY) National Provider Identifier (NPI) Medical License Number Medical License State Target Audience The intended audience for this activity is emergency physicians and other health care professionals involved treatment of patients with hyperkalemia. Degree (please specify) Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation activity. Vindico will apply to the American College of Physicians for program approval. In accordance with the Accreditation Council for Continuing Medical Education s Standards for Commercial Support, all planners, teachers and authors involved development of content are reuired to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience., topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee. 2016 istockphoto.com/guvendemir/kotoffei MD/DO PhD MD, PhD PharmD/RPh PA RN/BSN/MSN NP Industry Other: How did you hear about this meeting? (multiple selections allowed) E-mail Advertisement Postcard Brochure Web site Word of mouth ADA compliance: In compliance with the Americans with Disabilities Act of 1990, we will make reasonable efforts to accommodate persons with disabilities. Please call with your reuests. Specialty (select one) Internal Medicine Cardiology Nephrology Medicine Other: Endocrinology Family Practice/General Practice Activity Reuest YES, I would like to receive information regarding future / activities related to this therapeutic area. Priority Code: 283-1 2 3
Presorted First Class Mail US Postage PAID Permit # 906 Bellmawr NJ Professor and Associate Chair of Medicine Director, Clinical Research Service Center Wayne State University School of Medicine Detroit, MI Vice Chief of Medicine Baylor University Medical Center Dallas, TX W. Frank Peacock, MD, F, FACC Professor, Medicine Associate Chair and Research Director Baylor College of Medicine/Ben Taub General Hospital Houston, TX Register Online! South Convention Center VindicoMedEd.com/Xxxxxx Level 2 Director of Research, Denver Nephrology Research Colorado Kidney Care Denver, CO VINDICO medical education 6900 Grove Road Building 100 Updates on the Current Management of a Complex Condition /-certified Activity /-certified Activity Peter A. McCullough, MD, MPH W. Frank Peacock, MD This continuing medical education activity is provided by This activity is supported by an educational grant from ZS Pharma, Inc. This symposium is not part of the official 16 conference educational program as planned by s Educational Meetings Committee.